Interferon-beta not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells

European Cytokine Network

Volumn 8, Issue 4, 1997, Pages 345-349

  Coclet Ninin, Joëlle ^a   Dayer, Jean Michel ^a   Burger, Danielle ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b University Hospital   (Switzerland)

Author keywords

Inflammation; Interferon ; Interleukin 1 receptor antagonist; Interleukin 1 ; TNF soluble receptors; Tumor necrosis factor

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NORMAL HUMAN;

HUMANS; INTERFERON-BETA; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; PHYTOHEMAGGLUTININS; RECEPTORS, INTERLEUKIN-1; STIMULATION, CHEMICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031463988     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Lucas K, Hohlfeld R. 1995. Differential aspects of cytokines in the immunopathology of multiple sclerosis. Neurology 45: S4.
2. Dinarello C A. 1996. Biologic basis for interleukin-1 in disease. (Review) Blood 87: 2095.
3. Feldmann M, Brennan F M, Maini R N. 1996. Role of cytokines in rheumatoid arthritis. (Review) Annu. Rev. Immunol. 14: 397.
4. Brennan F M, Feldmann M. 1996. Cytokines in autoimmunity. (Review) Curr. Opin. Immunol. 8: 872.
5. Dayer J M, Arend W P. 1997. Cytokines and growth factors. In: Kelley W N, Harris E D, Ruddy S, Sledge C S, Eds. Textbook of Rheumatology. Philadelphia: WB Saunders, 267.
6. Burger D, Dayer J M. 1995. Inhibitory cytokines and cytokine inhibitors. (Review) Neurology 45: S39.
7. Seckinger P, Lowenthal J W, Williamson K, Dayer J M, MacDonald H R. 1987. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J. Immunol. 139: 1546.
8. Colotta F, Dower S K, Sims J E, Mantovani A. 1994. The type II "decoy" receptor: a novel regulatory pathway for interleukin-1. (Review) Immunol. Today 15: 562.
9. Reder A T, Ed. 1997. Interferon Therapy of Multiple Sclerosis. New York: Marcel Dekker, Inc. 1.
10. Pfeffer L M, Constantinescu S N. 1997. The molecular biology of interferon-beta from receptor binding to transmembrane signaling. In: Reder A T, Eds. Interferon Therapy of Multiple Sclerosis. New York: Marcel Dekker, Inc. 1.
11. Van Damme J, De Ley M, Van Snick J, Dinarello C A, Billiau A. 1987. The role of interferon-beta 1 and the 26 kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin-1 and tumor necrosis factor. J. Immunol. 139: 1867.
12. Van Damme J, Schaafsma M R, Fibbe W E, Falkenburg J H, Opdenakker G, Billiau A. 1989. Simultaneous production of interleukin-6, interferon-beta and colony-stimulating activity by fibroblasts after viral and bacterial infection. Eur. J. Immunol. 19: 163.
13. Reis L F, Ho Lee T, Vilcek J, 1989. Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts. J. Biol. Chem. 264: 16351.
14. Dean R T, Virelizier J L. 1983. Interferon as a macrophage activating factor. I. Enhancement of cytotoxicity by fresh and matured human monocytes in the absence of other soluble signals. Clin. Exp. Immunol. 51: 501.
15. Von Hoegen P, Zawutzky R, Schirrmacher V. 1990. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolylic T cell activity via induction of interferon-alpha/beta. Cell Immunol. 126: 80.
16. Shalaby M R, Weck P K, Rinderknecht E, Harkins R N, Frane J W, Ross M J. 1984. Effects of bacteria-produced human alpha, beta, and gamma interferons on in vitro immune functions. Cell Immunol. 84: 380.
17. Siegel D S, Le J, Vilcek J. 1986. Modulation of lymphocyte proliferation and immunoglobulin synthesis by interferon-gamma and "type I" interferons. Cell Immunol. 101: 380.
18. Rudick R A, Carpenter C S, Cookfair D L, Tuohy V K, Ransohoff R M. 1993. In vitro and in vivo inhibition of mitogen-driven T cell activation by recombinant interferon-beta. Neurology 43: 2080.
19. Hertzog P J, Johns T G, Callister K A, Dinatale A, Linnane A W. 1990. Comparative antiproliferative and receptor binding activities of interferons-alpha and -beta on lymphoblastoid and melanoma cells. Biochem. Int. 22: 1095.
20. Schiller J H, Groveman D S, Schmid S M, Willson J K, Cummings K B, Borden E C. 1986. Synergistic antiproliferative effects of human recombinant alpha 54-or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis. Cancer Res. 46: 483.
21. Knight E Jr, Anton E D, Fahey D, Friedland B K, Jonak G J. 1985. Interferon regulates c-myc gene expression in Daudi cells at the post-transcriptional level. Proc. Natl. Acad. Sci. USA 82: 1151.
22. Pfeffer L M, Tamm I. 1983. Comparison of the effects of alpha and beta interferons on the proliferation and volume of human tumor cells (HeLa-S3, Daudi, P3HR-1). J. Interferon Res. 3: 395.
23. Krasagakis K, Garbe C, Kruger S, Orfanos C E. 1991. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not -alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J. Invest. Dermatol. 97: 364.
24. Porrini A M, Gambi D, Reder A T. 1995. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 61: 27.
25. Rep M H, Hintzen R Q, Polman C H, van Lier R A. 1996. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T cells. J. Neuroimmunol. 67: 111.
26. Vey E, Zhang J H, Dayer J M. 1992. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J. Immunol. 149: 2040.
27. Maizel A L, Mehta S, Ford R J. 1979. T lymphocyte/monocyte interaction in response to phytohemagglutinin. Cell Immunol. 48: 383.
28. Aggarwal B B, Natarajan K. 1996. Tumor necrosis factors: development during the last decade. (Review) Eur. Cvtokine Netw. 7:93.
29. Wallach D. 1996. A decade of accumulated knowledge and emerging answers. The 6th international congress on TNF Rhodes, Greece, May 1996. Eur: Cytokine Netw. 7: 713.
30. Smith M F Jr, Eidlen D, Brewer M T, Eisenberg S P, Arend W P, Gutierrez-Hartmann A. 1992. Human IL-1 receptor antagonist promoter. Cell type-specific activity and identification of regulatory regions. J. Immunol. 149: 2000.
31. Vey E, Dayer J M, Burger D. 1997. Direct contact with stimulated T cells induces the expression of IL-1 beta and IL-1 receptor antagonist in human monocytes. Involvement of serine/threonine phosphatases in differential regulation. Cytokine 9: 480.
32. Nicoletti F, Patti F, DiMarco R, Zaccone P, Nicoletti A, Meroni P, Reggio A. 1996. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 8: 395.
33. Brod S A, Marshall G D, Henninger E M, Sriram S, Khan M, Wolinsky J S. 1996. Interferon-beta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 46: 1633.
34. Noronha A, Toscas A, Jensen M A. 1993. Interferon-beta decreases T cell activation and interferon -gamma production in multiple sclerosis. J. Neuroimmunol. 46: 145.
35. Abu Khabar K S, Armstrong J A, Ho M. 1992. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J. Leukoc. Biol. 52: 165.
36. Tilg H, Vogel W, Dinarello C A. 1995. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 85: 433.
37. Platanias L C, Uddin S, Domanski P, Colamonici O R. 1996. Differences in interferon-alpha and -beta signaling. Interferon-beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J. Biol. Chem. 271: 23630.
38. Abramovich C, Shulman L M, Ratovitski E, Harroch S, Tovey M, Eid P, Revel M. 1994. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. EMBO J. 13: 5871.
39. Jenkins J K, Malyak M, Arend W P. 1994. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1β production in human monocytes and neutrophils. Lymphokine Cytokine Res. 13: 47.
40. Hartung H P, Kieseier B C. 1996. Targets for the therapeutic action of interferon-beta in multiple sclerosis [editorial]. Ann. Neurol. 40: 825.
41. Arnason B G, Dayal A, Qu Z X, Jensen M A, Gene K, Reder A T. 1996. Mechanisms of action of interferon-beta in multiple sclerosis. (Review) Springer Semin. Immunopathol. 18: 125.
42. Hall G L, Compston A, Scolding N J. 1997. Beta-interferon and multiple sclerosis. (Review) Trends Neurosci. 20: 63.